Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally with more than 33 million patients diagnosed, taking more than a million lives. Abundant mutations were observed but the functional consequences of these mutations are largely unknown. We report the mutation spectrum, replication dynamics, and infectivity of 11 patient-derived viral isolates in diverse cell lines, including the human lung cancer cell line Calu-3. We observed 46 mutations, including 9 different mutations in the spike gene. Importantly, these viral isolates show significant and consistent variations in replication dynamics and infectivity in tested cell lines, up to a 1500-fold difference in viral titers at 24 h after infecting Calu-3 cells. Moreover, we show that the variations in viral titers among viral isolates are positively correlated with blood clotting function but inversely correlated with the amount of red blood cell and hemoglobin in patients. Therefore, we provide direct evidence that naturally occurring mutations in SARS-CoV-2 can substantially change its replication dynamics and infectivity in diverse human cell lines, with clinical implications in vivo.

Highlights

  • IntroductionAs of September 29, 2020, SARS-CoV-2 has infected more than 33 million people around the world with a death toll growing to more than a million

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic

  • We showed that the variations in viral titers among viral isolates are positively correlated with blood clotting function but inversely correlated with the amount of red blood cell and hemoglobin in patients

Read more

Summary

Introduction

As of September 29, 2020, SARS-CoV-2 has infected more than 33 million people around the world with a death toll growing to more than a million. More than half of patients with SARS-CoV-2 were asymptomatic[1], who can still transmit the Coronavirus Disease-2019 (COVID-19) disease[2,3], making it much more challenging to prevent. There is clearly an urgent need to develop effective vaccines or antibody-based therapeutics against SARS-Cov-24,5. According to the report from the World Health Organization, there are currently 40 candidate vaccines in clinical evaluation and 151 candidate vaccines in preclinical development (https://www.who.int/publications/m/item/draftlandscape-of-covid-19-candidate-vaccines, accessed September 29th, 2020)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call